Skip to main content

Labcorp vs Quest Diagnostics: Strategic Comparison

Direct Answer

Labcorp is the bigger company by revenue: $13.95 billion in fiscal 2025 versus Quest Diagnostics' $11.035 billion, a gap of about 26%. Quest is the more profitable one, with a 9.0% net margin and $992 million of net income in FY2025 against Labcorp's 6.3% margin and $876.5 million. Labcorp also employs more people, about 71,000 versus Quest's nearly 57,000, but Quest's market capitalization was slightly higher, around $27.2 billion versus Labcorp's roughly $25.1 billion in September 2026.

Labcorp and Quest Diagnostics run the two biggest independent clinical lab networks in the United States, together controlling roughly half of the independent lab market and sending samples through rival fleets of patient service centers and courier aircraft out of Burlington, North Carolina and Secaucus, New Jersey. Labcorp traces back to a 1995 merger of National Health Laboratories and Roche Biomedical Laboratories, while Quest was spun off from Corning in 1996 after starting life as Dr. Paul A. Brown's Metropolitan Pathology Laboratory in 1967. Labcorp, led by Chairman and CEO Adam H. Schechter since November 2019, reported $13.95 billion in revenue and $876.5 million in net income for fiscal 2025, with about 71,000 employees. Quest, led by Chairman, President and CEO Jim Davis since November 2022, reported $11.035 billion in revenue and $992 million in net income for fiscal 2025, with nearly 57,000 employees. Labcorp sells more because it also runs a separate Biopharma Laboratory Services segment that Quest doesn't have, but Quest converts more of each sales dollar into profit.

Editorial research by Swet Parvadiya. Figures keep each company's fiscal year; amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Sources are listed below.

Share

Key Differences at a Glance

FieldLabcorp Holdings Inc.Quest Diagnostics Incorporated
Latest annual revenue$14.0B (FY2025)$11.0B (FY2025)
Founded19951967
Employees71,00057,000
Market Cap$25.1B$27.2B
HeadquartersUnited StatesUnited States
Revenue / Employee$197k / employee$194k / employee
Valuation Multiple1.8x P/S2.5x P/S

Strategic Positioning

Business model and competitive context from the cited profiles

Labcorp Holdings Inc. Strategic Vector

FY2025 Revenue Baseline

Labcorp's growth now comes less from routine test volume and more from mix: specialty oncology and genetic tests, hospital outreach acquisitions that move whole lab books onto its network, and consumer channels. That mix shift is why adjusted operating margin expanded to 15.8% in Q2 2026 even as Medicare pricing stays uncertain.

Productivity: $197k / employee

Quest Diagnostics Incorporated Strategic Vector

FY2025 Revenue Baseline

Quest Diagnostics Incorporated's long-term commercial strategy prioritizes scaling high-margin growth vectors while actively mitigating structural industry risks. In terms of growth initiatives, management is allocating capital toward ad-detect alzheimer's blood tests could open multi-billion dollar diagnostic market as disease-modifying therapies emerge, where quest's AD-Detect Alzheimer's blood tests (pTau-217 and related biomarkers) have demonstrated high accuracy in peer-reviewed clinical studies. Concurrently, the organization focuses on navigating market pressures around fda regulation of laboratory-developed tests could increase compliance costs and delay test launches, addressing environments where the FDA has expressed increasing interest in regulating laboratory-developed tests (LDTs) as medical devices, which would require premarket review for many of Quest's advanced diagnostics. By maintaining disciplined capital allocation and operational rigor, Quest Diagnostics Incorporated aims to protect its unit economics and preserve its economic moat across changing market cycles.

Productivity: $194k / employee
Comparative Divergence: Industry trackers describe Labcorp and Quest as a long-running duopoly that together holds close to half of independent U.S. lab revenue and roughly 80% of the hospital-outreach lab market, a position built through decades of competing acquisitions of regional labs and hospital lab-management contracts. Both companies spent 2025 and 2026 buying hospital outreach businesses to add volume: Quest signed deals with NewYork-Presbyterian, Corewell Health and Fresenius Medical Care's dialysis labs, while Labcorp closed 13 health-system and regional lab transactions in 2025, including Baystate Health and Providence, and added outreach assets from Crouse Health and Parkview Health in 2026. Both also pushed into higher-margin specialty and consumer testing at the same time: Quest's AI Companion tool and Haystack MRD oncology test (New York State-approved in 2026) mirror Labcorp's ColoSense colorectal screening and Marker by Labcorp consumer genetic panel. Analysts covering Labcorp's 2026 earnings have explicitly credited the healthy diagnostics end-market for lifting both companies together, noting Quest's outperformance alongside Labcorp's own raised guidance.

Labcorp vs Quest Diagnostics Market Share

Labcorp Holdings Inc. market share
Labcorp Holdings Inc. is one of the premier market leaders in Clinical Laboratory Services and Biopharma Laboratory Services, commanding substantial market share and strong brand equity across its core geographic operating regions.
Quest Diagnostics Incorporated market share
Quest Diagnostics Incorporated is one of the premier market leaders in Clinical Laboratory Services / Diagnostic Information Services, commanding substantial market share and strong brand equity across its core geographic operating regions.

Quick Stats Comparison

MetricLabcorp Holdings Inc.Quest Diagnostics Incorporated
Revenue$14.0B (FY2025)$11.0B (FY2025)
Founded19951967
HeadquartersBurlington, North CarolinaSecaucus, New Jersey, United States
Market Cap$25.1B$27.2B
Employees71,00057,000
Revenue / Employee$197k / employee$194k / employee
Valuation Multiple1.8x P/S2.5x P/S

Labcorp Revenue vs Quest Diagnostics Revenue — Year by Year

YearLabcorp Holdings Inc.Quest Diagnostics IncorporatedHigher reported revenue
2025$14.0B$11.0BLabcorp Holdings Inc. (approx. USD)
2024$13.0B$9.9BLabcorp Holdings Inc. (approx. USD)
2023$12.2B$9.3BLabcorp Holdings Inc. (approx. USD)
2022$11.9B$9.9BLabcorp Holdings Inc. (approx. USD)
2021$13.1B$10.8BLabcorp Holdings Inc. (approx. USD)

Business Model Breakdown

Overview: Labcorp Holdings Inc. vs Quest Diagnostics Incorporated

This in-depth comparison examines Labcorp Holdings Inc. and Quest Diagnostics Incorporated across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Labcorp Holdings Inc. on its own, evaluating Quest Diagnostics Incorporated, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Labcorp Holdings Inc. and Quest Diagnostics Incorporated is widest.

On the headline numbers, annual revenue is $14.0B (FY2025) for Labcorp Holdings Inc. and $11.0B (FY2025) for Quest Diagnostics Incorporated, while their respective market capitalizations stand at $25.1B and $27.2B. Both Labcorp Holdings Inc. and Quest Diagnostics Incorporated are headquartered in United States. Their local markets and applicable rules may still differ.

Labcorp Holdings Inc.: Labcorp is one of the two largest independent clinical laboratory operators in the US, alongside Quest Diagnostics. Headquartered in Burlington, North Carolina, it has about 71,000 employees, serves clients in roughly 100 countries, and performed more than 750 million tests in 2025. Since spinning off its clinical development CRO business as Fortrea in 2023, the company reports two segments: Diagnostics Laboratories and Biopharma Laboratory Services.

Quest Diagnostics Incorporated: Quest Diagnostics is a Secaucus, New Jersey-based provider of diagnostic information services. It does not make drugs or run hospitals. It runs the labs that process blood, urine and tissue samples ordered by doctors, hospitals, employers and consumers, then sends results back through EHRs and the MyQuest app. Quest says it serves about one in three adult Americans and half the physicians and hospitals in the U.S. each year. Since 2024 it has also run LifeLabs in Canada. Quest Diagnostics was founded in 1967 in New York City by Dr. Paul A. Brown as Metropolitan Pathology Laboratory before spinning off from Corning in 1996 to become America’s largest commercial clinical diagnostic testing provider.

Business Models: How Labcorp Holdings Inc. and Quest Diagnostics Incorporated Make Money

Labcorp Holdings Inc. and Quest Diagnostics Incorporated pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Labcorp Holdings Inc. and Quest Diagnostics Incorporated.

Labcorp Holdings Inc. business model: Labcorp makes money in two segments. Diagnostics Laboratories ($10.88 billion of 2025 revenue, about 78%) collects specimens through roughly 2,000 patient service centers, in-office phlebotomists, and courier and aircraft routes, runs routine and specialty tests in automated labs, and bills commercial insurers, Medicare and Medicaid, physicians, hospitals, and consumers. Biopharma Laboratory Services ($3.10 billion, about 22%) earns contract fees from drug, biotech, and device companies for central-laboratory testing in clinical trials and early-development (preclinical) studies; it ended 2025 with an $8.72 billion backlog. Hospital lab management and outreach acquisitions feed additional volume into the diagnostics network.

Quest Diagnostics Incorporated business model: Quest Diagnostics earns fee-for-service revenue for lab tests ordered by physicians, hospitals, health plans, employers and consumers. Diagnostic Information Services (DIS) produced $2.978B of the company's $3.043B Q2 2026 revenue. Payment comes from commercial insurers, Medicare and Medicaid, hospitals that send it outreach or reference work, employers, and patients paying directly through questhealth.com. Volume drives the economics. Specimens collected at about 2,200 patient service centers and physician offices are moved by courier, and on some routes by air, to regional labs. High-throughput automated testing there keeps the cost per test low. Routine tests such as metabolic panels, lipid panels and blood counts make up most of the volume. Advanced diagnostics like AD-Detect Alzheimer's blood tests, Haystack MRD, genetics and cardiometabolic panels carry higher prices. Hospital outreach acquisitions and Co-Lab lab-management deals add volume.

Competitive Advantage: Labcorp Holdings Inc. vs Quest Diagnostics Incorporated

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Labcorp Holdings Inc. stack up against those of Quest Diagnostics Incorporated.

Labcorp Holdings Inc. competitive advantage: Labcorp's edge is physical density plus breadth. About 2,000 patient service centers, more than 6,000 in-office phlebotomists, a nightly aircraft fleet out of Burlington, and large automated hub labs keep cost per test low. On top of that sits a specialty menu (oncology, women's health, genetics, neurology) and a central-lab business that supported more than 85% of new drugs and therapeutic products the FDA approved in 2025. A new entrant would need both the collection footprint and payer contracts to compete.

Quest Diagnostics Incorporated competitive advantage: Quest's main advantage is density. It has a national patient service center footprint, in-network contracts with most major U.S. health plans, EHR connections to physician offices, and regional labs that spread fixed costs across hundreds of millions of tests a year. Only Labcorp operates at comparable U.S. scale. That scale lets Quest offer health systems a lower-cost option for outreach testing. Deals with NewYork-Presbyterian, Corewell Health and Fresenius Medical Care show how it turns that into new volume.

Growth Strategy: Where Labcorp Holdings Inc. and Quest Diagnostics Incorporated Are Headed

Future prospects matter as much as current results. The growth strategies below explain how Labcorp Holdings Inc. and Quest Diagnostics Incorporated each plan to expand from here.

Labcorp Holdings Inc. growth strategy: Labcorp's stated priorities are leading in specialty testing, being the partner of choice for health systems and regional labs, growing consumer health, and using technology and AI to cut cost. In 2025 it launched more than 130 new tests and signed or closed 13 health-system and regional lab transactions; 2026 deals include outreach assets from Crouse Health, Parkview Health, and Tribal Diagnostics. The MyLabcorp app and Labcorp OnDemand push direct-to-consumer testing.

Quest Diagnostics Incorporated growth strategy: Quest is growing in four ways. First, it buys hospital outreach labs and signs Co-Lab Solutions lab-management deals, such as its Corewell Health joint venture in Michigan. Second, it adds large partner volume, such as dialysis testing for Fresenius Medical Care. Third, it pushes higher-value advanced diagnostics, including AD-Detect Alzheimer's blood tests, Haystack MRD (approved by New York State in 2026) and liver fibrosis testing. Fourth, it sells consumer-initiated tests through questhealth.com and wearable and wellness partners. Automation and AI in specimen processing, cervical cancer screening and the IntelliDraw collection tool are meant to offset reimbursement pressure.

Financial Picture: Labcorp Holdings Inc. vs Quest Diagnostics Incorporated

A closer look at the financial trajectory of Labcorp Holdings Inc. and Quest Diagnostics Incorporated rounds out the comparison.

Labcorp Holdings Inc.: Revenue rose from $13.01 billion in 2024 to $13.95 billion in 2025 (up 7.2%), with diluted EPS of $10.46, adjusted EPS of $16.44, and free cash flow of $1.21 billion. Momentum carried into 2026: second-quarter revenue reached $3.73 billion (up 5.8%, 4.2% organic), adjusted operating margin widened 70 basis points to 15.8%, and adjusted EPS climbed 14.9% to $4.99. In July 2026 management raised full-year guidance to 5.4%-6.3% revenue growth and adjusted EPS of $18.10-$18.55, and the board added $1.0 billion to the buyback authorization. Laboratory Corporation of America Holdings (Labcorp) is a dominant American healthcare diagnostics and clinical lab network, commanding a market valuation typically over $18 billion.

Quest Diagnostics Incorporated: Quest's results follow three phases. Before the pandemic, revenue grew slowly, from $7.21B in 2016 to $7.73B in 2019. COVID-19 testing then lifted revenue to $10.79B and net income to $1.995B in 2021. Revenue fell back to $9.25B in 2023 as that demand faded. Acquisitions and organic volume restarted growth: revenue reached $9.87B in 2024 and $11.035B in 2025, when operating income was $1.556B and operating cash flow was $1.886B. In the first half of 2026, revenue rose 9.7% to $5.938B and net income attributable to Quest rose 13.9% to $572M. Quest raised its quarterly dividend 7.5% to $0.86 per share in 2026. Quest Diagnostics Incorporated is a colossal American clinical laboratory operating a massive national network, sustaining a market valuation typically over $15 billion.

Company-Specific SWOT Notes

Labcorp Holdings Inc.

Strength

About 2,000 patient service centers, more than 6,000 in-office phlebotomists, and automated hub labs let Labcorp process more than 750 million tests a year at low unit cost.

Strength

Labcorp supported more than 85% of new drugs and therapeutic products approved by the FDA in 2025.

Weakness

Routine diagnostic testing faces pricing pressure from Medicare reimbursement cuts under PAMA and commercial payer cost management.

Weakness

Biopharma demand tracks pharma and biotech R&D budgets.

Opportunity

Labcorp launched more than 130 innovative new tests in 2025, expanding in oncology, women's health, neurology, and autoimmune diseases.

Threat

The Protecting Access to Medicare Act (PAMA) has reduced clinical laboratory fee schedule rates and further cuts are possible.

Quest Diagnostics Incorporated

Strength

Quest Diagnostics maintains the most comprehensive clinical laboratory database in the world, with data on over 65% of the U.S. population accumulated through decades of testing.

Strength

Quest operates over 2,200 patient service centers across the United States, providing geographic coverage and patient convenience that regional laboratories and hospital labs cannot match.

Weakness

The Protecting Access to Medicare Act (PAMA) of 2014 implemented market-based pricing that has reduced Medicare reimbursement for many common tests.

Weakness

Clinical laboratory testing remains labor-intensive despite automation investments.

Opportunity

Quest's AD-Detect Alzheimer's blood tests (pTau-217 and related biomarkers) have demonstrated high accuracy in peer-reviewed clinical studies.

Threat

The FDA has expressed increasing interest in regulating laboratory-developed tests (LDTs) as medical devices, which would require premarket review for many of Quest's advanced diagnostics.

Factual Scorecard

CategoryResultWhy
Same-period Revenue ScaleLabcorp Holdings Inc.$14.0B (FY2025) versus $11.0B (FY2025); the higher figure is identified after approximate USD conversion.
Founded EarlierQuest Diagnostics IncorporatedLabcorp Holdings Inc. was founded in 1995; Quest Diagnostics Incorporated was founded in 1967.
Verdict

Comparison Takeaway: Labcorp vs Quest Diagnostics

Labcorp's extra size comes largely from a business Quest doesn't run at all: Biopharma Laboratory Services, which brought in $3.10 billion in 2025 (about 22% of revenue) running central-lab testing for drug trials, versus Quest's single-minded focus on diagnostics for patients, physicians and hospitals. That diversification cuts both ways. Quest's pure diagnostics model posted the stronger FY2025 revenue growth, 11.8% versus Labcorp's 7.2%, boosted by its 2024 purchase of Canada's LifeLabs, while Labcorp's Biopharma segment grew Early Development revenue only slowly and even fell 13.5% in one 2025 quarter, showing how pharma R&D cycles can drag on its growth rate. On profitability, Quest wins clearly: its 9.0% net margin in FY2025 beat Labcorp's 6.3%, a gap that held in 2024 too (8.8% versus 5.7%). Labcorp's counter-argument is scale and specialty depth: it ran more than 750 million tests in 2025 and says it supported over 85% of new FDA-approved drugs that year through its biopharma arm, a diversification Quest cannot match.

Methodology and sourcing reviewed by Swet Parvadiya. No date is shown unless this comparison has its own editorial review date.

Frequently Asked Questions: Labcorp vs Quest Diagnostics

Is Labcorp bigger than Quest Diagnostics?

By revenue, yes. Labcorp reported $13.95 billion in fiscal 2025 compared with Quest Diagnostics' $11.035 billion, about 26% more. Labcorp also has more employees, roughly 71,000 versus Quest's nearly 57,000. But Quest edged out Labcorp on market capitalization, around $27.2 billion versus $25.1 billion in September 2026, and on net income, $992 million versus Labcorp's $876.5 million.

Which has better profit margins, Labcorp or Quest Diagnostics?

Quest Diagnostics. Its FY2025 net margin was 9.0% ($992 million of net income on $11.035 billion of revenue), versus Labcorp's 6.3% ($876.5 million on $13.95 billion). The gap was similar in FY2024, when Quest's margin was 8.8% against Labcorp's 5.7%, so Quest has consistently converted more of each revenue dollar into profit.

Who runs Labcorp and Quest Diagnostics?

Adam H. Schechter has been Labcorp's President and CEO since November 2019 and added the Chairman role in May 2020; he previously served on Labcorp's board starting in 2013. Jim Davis has been Quest Diagnostics' CEO since November 1, 2022, succeeding Steve Rusckowski, and became Chairman on April 1, 2023.

What's the difference between Labcorp and Quest Diagnostics' businesses?

Quest Diagnostics is purely a diagnostics company serving physicians, hospitals and consumers through about 2,200 patient service centers. Labcorp runs the same kind of diagnostics work through roughly 2,000 patient service centers, but it also operates a separate Biopharma Laboratory Services segment that ran central-lab testing for drug trials and generated $3.10 billion, or about 22% of Labcorp's 2025 revenue, with an $8.72 billion backlog. Quest has no comparable biopharma segment.

Which is better, Labcorp or Quest Diagnostics?

It depends what you're measuring. Labcorp is the larger, more diversified company, with $13.95 billion of FY2025 revenue and a biopharma lab-services arm Quest lacks. Quest Diagnostics is the more profitable and faster-growing one, posting a 9.0% net margin and 11.8% revenue growth in FY2025 versus Labcorp's 6.3% margin and 7.2% growth, partly thanks to its 2024 LifeLabs acquisition in Canada.

Which company was founded first, Labcorp Holdings Inc. or Quest Diagnostics Incorporated?

Quest Diagnostics Incorporated was founded in 1967; Labcorp Holdings Inc. was founded in 1995.

What revenue did Labcorp Holdings Inc. and Quest Diagnostics Incorporated report?

Labcorp Holdings Inc. had $14.0B (FY2025), while Quest Diagnostics Incorporated had $11.0B (FY2025). These figures describe revenue scale; they do not by themselves determine an overall winner.

How do Labcorp Holdings Inc. and Quest Diagnostics Incorporated make money?

Labcorp Holdings Inc.: Labcorp makes money in two segments. Quest Diagnostics Incorporated: Quest Diagnostics earns fee-for-service revenue for lab tests ordered by physicians, hospitals, health plans, employers and consumers.

Which is better, Labcorp Holdings Inc. or Quest Diagnostics Incorporated?

There is no evidence-based single winner. Compare Labcorp Holdings Inc. and Quest Diagnostics Incorporated on the same fiscal period and the metric relevant to the question, such as revenue, profitability, growth, product fit, or market value.

Sources & References

Quick Answer

Labcorp is the bigger company by revenue: $13.95 billion in fiscal 2025 versus Quest Diagnostics' $11.035 billion, a gap of about 26%. Quest is the more profitable one, with a 9.0% net margin and $992 million of net income in FY2025 against Labcorp's 6.3% margin and $876.5 million. Labcorp also employs more people, about 71,000 versus Quest's nearly 57,000, but Quest's market capitalization was slightly higher, around $27.2 billion versus Labcorp's roughly $25.1 billion in September 2026.

Verdict

Labcorp's extra size comes largely from a business Quest doesn't run at all: Biopharma Laboratory Services, which brought in $3.10 billion in 2025 (about 22% of revenue) running central-lab testing for drug trials, versus Quest's single-minded focus on diagnostics for patients, physicians and hospitals. That diversification cuts both ways. Quest's pure diagnostics model posted the stronger FY2025 revenue growth, 11.8% versus Labcorp's 7.2%, boosted by its 2024 purchase of Canada's LifeLabs, while Labcorp's Biopharma segment grew Early Development revenue only slowly and even fell 13.5% in one 2025 quarter, showing how pharma R&D cycles can drag on its growth rate. On profitability, Quest wins clearly: its 9.0% net margin in FY2025 beat Labcorp's 6.3%, a gap that held in 2024 too (8.8% versus 5.7%). Labcorp's counter-argument is scale and specialty depth: it ran more than 750 million tests in 2025 and says it supported over 85% of new FDA-approved drugs that year through its biopharma arm, a diversification Quest cannot match.

Cite This Page

Automatically generated citations for researchers.

APA Format

CorpDigest. (2026). Labcorp Holdings Inc. vs Quest Diagnostics Incorporated Comparison. from https://corpdigest.com/compare/labcorp-vs-quest-diagnostics

MLA Format

CorpDigest. "Labcorp Holdings Inc. vs Quest Diagnostics Incorporated Comparison." CorpDigest, 2026, https://corpdigest.com/compare/labcorp-vs-quest-diagnostics.

Chicago Format

CorpDigest. "Labcorp Holdings Inc. vs Quest Diagnostics Incorporated Comparison." CorpDigest. 2026. https://corpdigest.com/compare/labcorp-vs-quest-diagnostics.

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.